Geode Capital Management
STOK icon

Geode Capital Management’s Stoke Therapeutics STOK Stock Holding History

Geode Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.9M Buy
1,524,309
+202,049
+15% +$6.48M ﹤0.01% 1629
2026
Q1 		$43.1M Buy
1,322,260
+156,115
+13% +$5.12M ﹤0.01% 1574
2025
Q4 		$37M Buy
1,166,145
+19,145
+2% +$576K ﹤0.01% 1668
2025
Q3 		$27M Buy
1,147,000
+174,079
+18% +$2.98M ﹤0.01% 1845
2025
Q2 		$11M Buy
972,921
+70,935
+8% +$674K ﹤0.01% 2298
2025
Q1 		$6M Buy
901,986
+24,891
+3% +$232K ﹤0.01% 2572
2024
Q4 		$9.68M Buy
877,095
+6,264
+0.7% +$77K ﹤0.01% 2401
2024
Q3 		$10.7M Buy
870,831
+76,661
+10% +$1.09M ﹤0.01% 2337
2024
Q2 		$10.7M Buy
794,170
+154,363
+24% +$2.08M ﹤0.01% 2280
2024
Q1 		$8.64M Buy
639,807
+24,083
+4% +$146K ﹤0.01% 2409
2023
Q4 		$3.24M Buy
615,724
+24,607
+4% +$105K ﹤0.01% 2911
2023
Q3 		$2.33M Sell
591,117
-8,663
-1% -$57K ﹤0.01% 3023
2023
Q2 		$6.38M Buy
599,780
+113,100
+23% +$1.2M ﹤0.01% 2560
2023
Q1 		$4.05M Buy
486,680
+12,456
+3% +$112K ﹤0.01% 2729
2022
Q4 		$4.38M Buy
474,224
+13,969
+3% +$145K ﹤0.01% 2734
2022
Q3 		$5.91M Buy
460,255
+16,446
+4% +$262K ﹤0.01% 2580
2022
Q2 		$5.86M Buy
443,809
+8,038
+2% +$122K ﹤0.01% 2613
2022
Q1 		$9.17M Buy
435,771
+59,617
+16% +$1.19M ﹤0.01% 2405
2021
Q4 		$9.02M Buy
376,154
+12,819
+4% +$306K ﹤0.01% 2517
2021
Q3 		$9.24M Buy
363,335
+7,089
+2% +$198K ﹤0.01% 2501
2021
Q2 		$12M Buy
356,246
+63,210
+22% +$2.23M ﹤0.01% 2334
2021
Q1 		$11.4M Buy
293,036
+21,871
+8% +$1.25M ﹤0.01% 2271
2020
Q4 		$16.8M Buy
271,165
+68,976
+34% +$3.16M ﹤0.01% 1830
2020
Q3 		$6.77M Buy
202,189
+42,245
+26% +$1.21M ﹤0.01% 2211
2020
Q2 		$3.81M Sell
159,944
-25,912
-14% -$615K ﹤0.01% 2495
2020
Q1 		$4.26M Buy
185,856
+66,139
+55% +$1.63M ﹤0.01% 2235
2019
Q4 		$3.39M Buy
119,717
+6,965
+6% +$175K ﹤0.01% 2686
2019
Q3 		$2.42M Buy
+112,752
New +$3.14M ﹤0.01% 2820

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management's STOK Position: Q2 2026 in Review

Geode Capital Management increased its Stoke Therapeutics (STOK) stake by 15% in Q2 2026, buying an estimated $6.48M and bringing the position to 1,524,309 shares worth $49.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1629.

Geode Capital Management first reported a position in STOK in Q3 2019 and has held it in 28 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Geode Capital Management held 1,524,309 shares of Stoke Therapeutics worth $49.9M as of Q2 2026.
  • Geode Capital Management bought 202,049 Stoke Therapeutics shares in Q2 2026, an estimated $6.48M.
  • Stoke Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1629 holding.
  • Geode Capital Management first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.